

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>VEDANTA PARTNERS, LLC</u> (Last) (First) (Middle) C/O VEDANTA MANAGEMENT LP 250 WEST 55TH STREET, SUITE 13D (Street) NEW YORK NY 10019 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>REVIVA PHARMACEUTICALS HOLDINGS, INC. [RVPH]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 06/01/2021	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	06/01/2021		P		931,000	A	\$3.75 ⁽¹⁾	931,000	I	See Footnotes ⁽²⁾⁽⁶⁾
Common Stock	06/01/2021		P		399,000	A	\$3.75 ⁽¹⁾	399,000	I	See Footnotes ⁽³⁾⁽⁷⁾
Common Stock								99,539	I	See Footnotes ⁽⁴⁾⁽⁷⁾
Common Stock								871,337	I	See Footnote ⁽⁵⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Warrants (right to buy)	\$4.125	06/01/2021		P		931,000		06/01/2021	06/01/2026	Common Stock	698,250	(1)	931,000	I	See Footnotes ⁽²⁾⁽⁶⁾
Warrants (right to buy)	\$4.125	06/01/2021		P		399,000		06/01/2021	06/01/2026	Common Stock	299,250	(1)	399,000	I	See Footnotes ⁽³⁾⁽⁷⁾

1. Name and Address of Reporting Person*
VEDANTA PARTNERS, LLC
 (Last) (First) (Middle)
 C/O VEDANTA MANAGEMENT LP
 250 WEST 55TH STREET, SUITE 13D
 (Street)
 NEW YORK NY 10019
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Vedanta Associates-R, LP
 (Last) (First) (Middle)
 C/O VEDANTA MANAGEMENT LP
 250 WEST 55TH STREET, SUITE 13D
 (Street)
 NEW YORK NY 10019
 (City) (State) (Zip)

1. Name and Address of Reporting Person*		
VEDANTA ASSOCIATES, L.P.		
(Last)	(First)	(Middle)
C/O VEDANTA MANAGEMENT LP		
250 WEST 55TH STREET, SUITE 13D		
(Street)		
NEW YORK	NY	10019
(City) (State) (Zip)		
1. Name and Address of Reporting Person*		
BETA OPERATORS FUND, L.P.		
(Last)	(First)	(Middle)
C/O VEDANTA MANAGEMENT LP		
250 WEST 55TH STREET, SUITE 13D		
(Street)		
NEW YORK	NY	10019
(City) (State) (Zip)		
1. Name and Address of Reporting Person*		
SAXENA PARAG		
(Last)	(First)	(Middle)
C/O VEDANTA MANAGEMENT LP		
250 WEST 55TH STREET, SUITE 13D		
(Street)		
NEW YORK	NY	10019
(City) (State) (Zip)		

Explanation of Responses:

- The securities were purchased as a unit, with each unit consisting of one share of common stock and one warrant exercisable for 0.75 shares of common stock. The purchase price of each unit was \$3.75 per share.
- Held directly by Vedanta Associates-R, L.P. ("Vedanta Associates-R"). Vedanta Partners, LLC ("Vedanta Partners") is the general partner of Vedanta Associates-R, and Parag Saxena is the majority member of Vedanta Partners.
- Held directly by Beta Operators Fund, L.P. ("Beta Operators Fund"). Vedanta Associates, L.P. ("Vedanta Associates") is the general partner of Beta Operators Fund. Vedanta Partners is the general partner of Vedanta Associates, and Parag Saxena is the majority member of Vedanta Partners.
- Held directly by Vedanta Associates. Vedanta Partners is the general partner of Vedanta Associates, and Parag Saxena is the majority member of Vedanta Partners.
- Held directly by Mr. Saxena.
- Each of Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein.
- Each of Vedanta Associates, Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein.

[/s/ Parag Saxena - for Vedanta Partners, LLC, by Parag Saxena, its CEO](#) [06/03/2021](#)

[/s/ Parag Saxena - for Vedanta Associates-R, LP, by Vedanta Partners, LLC, its general partner, by Parag Saxena, its CEO](#) [06/03/2021](#)

[/s/ Parag Saxena - for Vedanta Associates, LP, by Vedanta Partners, LLC, its general partner, by Parag Saxena, its CEO](#) [06/03/2021](#)

[/s/ Parag Saxena - for Beta Operators Fund, L.P., by Vedanta Associates, LP, its general partner, by Vedanta Partners, LLC, its general partner, by Parag Saxena, its CEO](#) [06/03/2021](#)

[/s/ Parag Saxena](#) [06/03/2021](#)

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.